Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Influence of a Prematuration Culture With a Phosphodiesterase-3 Inhibitor (PDE3-I) on Embryonic Aneuploidy Rate and Developmental Potential

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by Universitair Ziekenhuis Brussel.
Recruitment status was  Not yet recruiting
Information provided by:
Universitair Ziekenhuis Brussel Identifier:
First received: January 13, 2009
Last updated: NA
Last verified: January 2009
History: No changes posted

A single centre randomised controlled trial investigating the influence of a novel prematuration system (PMS) using a phosphodiesterase-3 inhibitor for in-vitro maturation of oocytes

Condition Intervention Phase
Procedure: prematuration culture
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Influence of a Prematuration Culture With a PDE3-I on Embryonic Aneuploidy Rate and Developmental Potential

Resource links provided by NLM:

Further study details as provided by Universitair Ziekenhuis Brussel:

Primary Outcome Measures:
  • Incidence of aneuploidy rate by fluorescence in situ hybridisation (FISH) technique in 6 to 8 cell embryos from prolonged (PMC) IVM compared to conventional IVM on sibling oocytes. [ Time Frame: 3 days after egg retrieval ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Implantation potential of embryos from conventional IVM performed on Type II COC. Efficiency of both maturation systems in obtaining blastocysts. Endometrium quality in IVM cycles. [ Time Frame: 7 days after egg retrieval ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 240
Study Start Date: May 2009
Estimated Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: in-vitro maturation of oocytes Procedure: prematuration culture
The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a "prolonged" IVM (PMC)) in comparison to "conventional" IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.


Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy volunteers, either with PCOS/PCOS-like ovaries, or with normal ovaries, who undergo oocyte donation for research
  • AFC at least 10
  • AMH: > 5 μg/L
  • Female age < 36 years

Exclusion Criteria:

  • major uterine or ovarian abnormalities
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00823420

Contact: Johan Smitz, MD PhD

Centre for Reproductive Medicine Not yet recruiting
Brussels, Belgium
Contact: Johan Smitz, MD PhD   
Sponsors and Collaborators
Universitair Ziekenhuis Brussel
  More Information

No publications provided

Responsible Party: Professor Johan Smitz, Universitair Ziekenhuis Brussel Identifier: NCT00823420     History of Changes
Other Study ID Numbers: IWT-JSMDV2008
Study First Received: January 13, 2009
Last Updated: January 13, 2009
Health Authority: Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Keywords provided by Universitair Ziekenhuis Brussel:
PCOS and normal ovulatory patients
in-vitro maturation of oocytes

Additional relevant MeSH terms:
Chromosome Aberrations
Genital Diseases, Female
Genital Diseases, Male
Pathologic Processes
Phosphodiesterase 3 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Phosphodiesterase Inhibitors processed this record on November 20, 2014